Spots Global Cancer Trial Database for castration resistant prostatic cancer
Every month we try and update this database with for castration resistant prostatic cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | NCT05191017 | Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration Resi... Castration Resi... | NUV-422 Enzalutamide | 18 Years - | Nuvation Bio Inc. | |
| A Study of MGC026 in Participants With Advanced Solid Tumors | NCT06242470 | Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist... | MGC026 Dose Esc... MGC026 Dose for... | 18 Years - | MacroGenics | |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer | NCT04337580 | Prostate Cancer Refractory Canc... Castration Resi... | Omeprazole 80 m... | 18 Years - | Wake Forest University Health Sciences | |
| A Study of MGC026 in Participants With Advanced Solid Tumors | NCT06242470 | Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist... | MGC026 Dose Esc... MGC026 Dose for... | 18 Years - | MacroGenics | |
| Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects | NCT03248570 | Castration Resi... Metastatic Pros... | Pembrolizumab Chemotherapy | 18 Years - | University of California, San Francisco | |
| Prospective REgistry of Targeted RadionucLide TherapY in Patients With mCRPC (REALITY Study) | NCT04833517 | Prostate Cancer... Castration Resi... Advanced Prosta... | 18 Years - | Universität des Saarlandes | ||
| A Study of MGC026 in Participants With Advanced Solid Tumors | NCT06242470 | Advanced Solid ... Advanced Cancer Metastatic Canc... Squamous Cell C... Non Small Cell ... Small-cell Lung... Bladder Cancer Sarcoma Endometrial Can... Melanoma Castration Resi... Cervical Cancer Colorectal Canc... Gastric Cancer Gastro-esophage... Pancreas Cancer Clear Cell Rena... Hepatocellular ... Platinum-resist... | MGC026 Dose Esc... MGC026 Dose for... | 18 Years - | MacroGenics | |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer | NCT04337580 | Prostate Cancer Refractory Canc... Castration Resi... | Omeprazole 80 m... | 18 Years - | Wake Forest University Health Sciences | |
| Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | NCT05191017 | Prostate Cancer Prostatic Cance... Cancer of Prost... Cancer of the P... Prostate Neopla... Castrate Resist... Castration Resi... Castration Resi... | NUV-422 Enzalutamide | 18 Years - | Nuvation Bio Inc. | |
| Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair Defects | NCT03248570 | Castration Resi... Metastatic Pros... | Pembrolizumab Chemotherapy | 18 Years - | University of California, San Francisco | |
| Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer | NCT04337580 | Prostate Cancer Refractory Canc... Castration Resi... | Omeprazole 80 m... | 18 Years - | Wake Forest University Health Sciences | |
| Safety, Pharmacokinetics, and Preliminary Efficacy of AMX-500 in Metastatic Castration Resistant Prostate Cancer (mCRPC) | NCT05997615 | Hormone-refract... | AMX-500 (SAR446... | 18 Years - | Sanofi | |
| Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer | NCT04918810 | Castration Resi... | Docetaxel inter... Docetaxel stand... | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Biomarker-driven Intermittent Docetaxel Versus Standard-of-care (SOC) Docetaxel in Metastatic Castration-resistant Prostate Cancer | NCT04918810 | Castration Resi... | Docetaxel inter... Docetaxel stand... | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | NCT05519449 | Prostate Cancer Metastatic Cast... Castration Resi... | JANX007 | 18 Years - 100 Years | Janux Therapeutics | |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | NCT05519449 | Prostate Cancer Metastatic Cast... Castration Resi... | JANX007 | 18 Years - 100 Years | Janux Therapeutics |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
